RAPT
Companies
NASDAQ
Rapt Therapeutics Inc.
Health Care
$7.42
-$5.22 (-41.30%)
Price Chart
Overview
About RAPT
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Market Cap
$134.0M
Volume
6.7M
Avg. Volume
6.1M
P/E Ratio
-0.50968254
Dividend Yield
0.00%
Employees
131.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.74
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RAPT shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$134.0M
Volume6.7M
P/E Ratio-0.51
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 8, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025